Simplex Trading
ZVRA icon

Simplex Trading’s Zevra Therapeutics ZVRA Stock Holding History

Simplex Trading’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.65M Buy
324,500
+140,500
+76% +$1.56M ﹤0.01% 1259
2026
Q1 		$1.71M Buy
184,000
+19,600
+12% +$177K ﹤0.01% 1959
2025
Q4 		$1.47M Sell
164,400
-15,500
-9% -$147K ﹤0.01% 2234
2025
Q3 		$1.71M Buy
179,900
+68,100
+61% +$683K ﹤0.01% 2481
2025
Q2 		$984K Buy
111,800
+36,400
+48% +$295K ﹤0.01% 2797
2025
Q1 		$564K Sell
75,400
-82,200
-52% -$653K ﹤0.01% 3273
2024
Q4 		$1.31M Buy
157,600
+64,200
+69% +$548K ﹤0.01% 2582
2024
Q3 		$648K Buy
+93,400
New +$634K ﹤0.01% 3316
2024
Q2 		– Sell
-13,900
Closed -$80K – 10007
2024
Q1 		$80K Sell
13,900
-19,700
-59% -$121K ﹤0.01% 5822
2023
Q4 		$220K Buy
33,600
+4,600
+16% +$21.5K ﹤0.01% 4580
2023
Q3 		$139K Sell
29,000
-21,900
-43% -$109K ﹤0.01% 4757
2023
Q2 		$259K Sell
50,900
-41,400
-45% -$223K ﹤0.01% 4012
2023
Q1 		$507K Buy
92,300
+26,000
+39% +$138K ﹤0.01% 3252
2022
Q4 		$304K Buy
66,300
+4,100
+7% +$20.8K ﹤0.01% 3729
2022
Q3 		$388K Sell
62,200
-49,800
-44% -$282K ﹤0.01% 3770
2022
Q2 		$499K Buy
112,000
+11,100
+11% +$50.6K ﹤0.01% 3447
2022
Q1 		$507K Sell
100,900
-40,000
-28% -$255K ﹤0.01% 3827
2021
Q4 		$1.23M Buy
140,900
+12,600
+10% +$112K ﹤0.01% 2594
2021
Q3 		$1.71M Buy
128,300
+900
+0.7% +$9.07K ﹤0.01% 2375
2021
Q2 		$1.63M Buy
127,400
+126,593
+15,687% +$1.36M ﹤0.01% 2452
2021
Q1 		$742K Buy
+807
New +$7.05K ﹤0.01% 2808
2019
Q3 		– Sell
-11
Closed -$30K – 7996
2019
Q2 		$30K Buy
11
+8
+267% +$201 ﹤0.01% 5284
2019
Q1 		$8K Buy
+3
New +$110 ﹤0.01% 6295
2018
Q3 		– Hold
0
– -$1K – 8183
2018
Q2 		– Hold
0
– – – 7213

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Simplex Trading's ZVRA Position: Q4 2025 in Review

Simplex Trading sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 25,328 shares — an estimated $240K sold.

Simplex Trading first reported a position in ZVRA in Q4 2017 and held it in 18 quarters. The position peaked at $539K in Q3 2021. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Simplex Trading reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 25,328 Zevra Therapeutics shares in Q4 2025, an estimated $240K.
  • Simplex Trading first reported a position in Zevra Therapeutics in Q4 2017 and held it in 18 quarters.
  • Simplex Trading's Zevra Therapeutics position peaked at $539K in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.